Genomics Institute of the Novartis Research Foundation
Compounds and compositions as protein kinase inhibitors
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
IRM LLC Novartis AG
A A A A A A A A A A A A A A A A A A A A A C C A C C A C A A A A
A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P C07D C07D A61P C07D C07D A61P C07D A61P A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Zuosheng Xing Qiong Pamela Chengzhi Martin Xia Daniel Shenlin Yongping Qiang Gregory B. Paul Pingda Shifeng Guobao
Liu Wang Zhang Albaugh Zhang Sendzik Wang Poon Huang Xie Ding Chopiuk Renhowe Ren Pan Zhang